Our analysis revealed no significant difference in the proportion of KDR+/CD34+ HE cells among the non-treated control group and the bFGF-treated groups in which bFGF was added during the ME induction period, the HE induction period, or both periods (Fig. 1E). The gene discussed is FGF2; the disease is hereditary elliptocytosis.